Pharmaceutical company Zogenix, along with Battelle Memorial Institute, has announced new data that supports the value of the DosePro needle-free injection technology in delivering biologics. The new, positive data will be unveiled in four poster presentations at the 2013 American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference, taking place May 20-22 in San Diego, Calif. Included in the presentations will be two posters coauthored by Zogenix and MedImmune LLC, which is the global biologics research and development arm of AstraZeneca plc, as well as two posters coauthored by Zogenix and Battelle.
The data to be presented in these posters demonstrate that the DosePro technology is compatible with monoclonal antibodies formulations as well as a range of biologic formulation viscosities that are difficult to deliver through standard autoinjector technologies. The studies show that injection of these formulations were within the acceptable criteria for injection time and peak pressure and that, following injection, there were no changes in molecular integrity, observable tertiary structure, purity, or potency. The data additionally demonstrate that needle-free technology like DosePro has the potential to positively affect patient acceptance of self-injectable therapies, which leads to increased adoption and adherence of subcutaneously administered biologics.
“This new data represents an important step in addressing the need for delivery technology for biologics by demonstrating DosePro’s compatibility with the viscous formulations and the impact of needle-free delivery on patient confidence,” said John Turanin, vice president and general manager of DosePro Technology at Zogenix. “We believe the AAPS National Biotechnology Conference will be an excellent forum to introduce the DosePro system to potential biopharmaceutical partners looking for innovative delivery technology solutions for their current and future self-injection therapies.”
The four posters being presented at the conference are: Poster No. M1012, “In Vitro Integrity of Two Recombinant Human Monoclonal Antibodies after Instantaneous Injection by DosePro Delivery Technology”; Poster No. M1013, “Injection Performance Assessment of Monoclonal Antibody Formulation Viscosity Mimics Using an Instantaneous Injection Technology”; Poster No. T2010, “Adoption, Adherence and Preferences Regarding Injectable Drug Deliver by Patients with Rheumatoid Arthritis: Results of a Research Survey”; and Poster No. T2012, “Devices for Delivery of Viscous Protein Formulations and their Impact on Protein Structure.”
Battelle will be featuring the DosePro system at booth No. 413 at the AAPS National Biotechnology Conference. For information regarding licensing opportunities using the DosePro platform, contact Battelle at 800-201-2011 or solutions@battelle.org
For information about Zogenics, visit www.zogenics.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
